Please assess the completion status of the following clinical trial:

Trial Title: Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects;~2. Age \> 18 years;~3. Patients with steroid-dependent Crohn's disease, documented in the medical history, having suffered from at least one episode of relapse (CDAI \> 150) in the last 12 months. Patients should have been in clinical remission (CDAI \< 150) for at least four weeks, on stable therapy with at least 10 mg of methylprednisolone (or equivalent), or been on steroidal tapering after a recent relapse. Patients with intolerance or resistance to AZT/6-MP/MTX were eligible;~4. Patients willing and able to give written informed consent.~Exclusion Criteria:~1. Patients with Crohn's disease with intestinal sub-occlusion, or suspect of abdominal abscess, or with active perianal disease, or with clinically active disease at randomization (CDAI ≥150);~2. Patients already on therapy with immunosuppressant agents (AZT, 6-MP, MTX) for less than 4 months;~3. Patients having received therapy with infliximab (or other anti-TNF) in the previous 3 months;~4. Investigational treatments in the previous 3 months prior to randomization;~5. Pregnant women, or women who were not using valid birth-control measures, except those in surgical menopause; breast feeding;~6. Non collaborating subjects or those unable to be compliant with the treatment and the study schedules;~7. Severe concomitant diseases such as :~   1. patients with inadequate bone marrow reserve: WBC \< 3000 /mm3; PLTs \< 75000 /mm3; Hb \< 8 g/dl~  2. liver disease with total bilirubin ≥ 3 times the upper limit of normal (ULN), AST (GOT) ≥ 3x ULN, alkaline phosphatase ≥ 3x ULN~  3. renal disease with serum creatinine ≥ 3 mg/dl~  4. serious cardiac, allergic, lung, neurological diseases, neoplastic or pre-neoplastic disease~  5. diseases (other than Crohn's) requiring chronic steroid treatment;~8. Elective surgery already scheduled at the start of the study (NB: patients having undergone previous surgery for Crohn's disease could be enrolled, if the patient had fully recovered and had been in remission for at least 4 weeks);~9. Chronic use of alcohol; drug addiction;~10. Subjects with contra-indication to the use of steroids (i.e. systemic fungal infections);~11. Evidence of clostridium difficilis in the stools.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ery-dex (Type: EXPERIMENTAL): Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
- Placebo (Type: PLACEBO_COMPARATOR): placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).